# EDGAR Filing Document

**Accession Number:** 0001730463
**File Stem:** 0001193125-25-286209
**Filing Date:** 2025-11
**Character Count:** 55681
**Document Hash:** 1bf197cd3097117963d31d3fe699f48b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-286209.hdr.sgml**: 20251118

**ACCESSION NUMBER**: 0001193125-25-286209

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251118

**DATE AS OF CHANGE**: 20251118

**EFFECTIVENESS DATE**: 20251118

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Autolus Therapeutics plc
- **CENTRAL INDEX KEY:** 0001730463
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291621
- **FILM NUMBER:** 251495083

**BUSINESS ADDRESS:**
- **STREET 1:** THE MEDIAWORKS
- **STREET 2:** 191 WOOD LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W12 7FP
- **BUSINESS PHONE:** 44 20 3829 6230

**MAIL ADDRESS:**
- **STREET 1:** THE MEDIAWORKS
- **STREET 2:** 191 WOOD LANE
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W12 7FP

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Autolus Therapeutics Ltd
- **DATE OF NAME CHANGE:** 20180205

**As filed with the U.S. Securities and Exchange Commission on November 18, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Autolus Therapeutics plc
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **England and Wales** | **Not applicable** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**The MediaWorks** 

**191 Wood Lane** 

**White City** 

**London W12 7FP United Kingdom** 

**Tel: +44 20 3829 6230** 

**(Address of principal executive offices, including zip code)** 

**Autolus Therapeutics plc 2025 Employee Share Purchase Plan** 

**Autolus Therapeutics plc 2025 Inducement Plan** 

**Autolus Therapeutics plc 2018 Equity Incentive Plan** 

**(Full titles of the plans)** 

**Autolus Inc.** 

**15810 Gaither Drive** 

**Gaithersburg, Maryland 20877** 

**United States of America** 

**Tel: +1 240 801 3830** 

**(Name, address and telephone number, including area code, of agent for service)** 

***Copies to:***

---

| | |
|:---|:---|
| **Christian E. Plaza**<br> **Courtney T. Thorne**<br> **William DuVal**<br> **Cooley LLP**<br> **One Freedom Square, Reston Town Center**<br> **Reston, Virginia 20190-5640**<br> **+1 703 456 8000** | **Claire Keast-Butler**<br> **Cooley (UK) LLP**<br> **22 Bishopsgate**<br> **London EC2N 4BQ**<br> **United Kingdom**<br> **+44 20 7583 4055** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 (this "Registration Statement") is being filed by Autolus Therapeutics plc (the "Registrant") for the purpose of registering up to an aggregate of 16,645,656 of the Registrant's ordinary shares represented by American Depositary Shares ("ADSs"), comprising (i) 3,000,000 ADSs that may be issued pursuant to the Registrant's 2025 Employee Share Purchase Plan (the "2025 ESPP") (as further described below), (ii) 3,000,000 ADSs that may be issued pursuant to the Registrant's 2025 Inducement Plan (the "2025 Inducement Plan") (as further described below) and (iii) 10,645,656 additional ADSs that may be issued pursuant to the Registrant's 2018 Equity Incentive Plan (the "2018 Plan" and, collectively with the 2025 ESPP and the 2025 Inducement Plan, the "Plans") (as further described below).

The 2025 ESPP was adopted by the Registrant's Board of Directors (the "Board") on May 20, 2025, subject to stockholder approval, which was obtained at the Annual Meeting of Stockholders (the "2025 Annual Meeting") on June 26, 2025 (the "Effective Date"). This Registration Statement is being filed to register 3,000,000 ADSs under the 2025 ESPP.

On March 27, 2025, the Board adopted the 2025 Inducement Plan and reserved 3,000,000 ADSs to be used exclusively for grants of equity-based awards to such individuals who were not previously employees or directors of the Registrant as a material inducement to such individuals' entry into employment with the Registrant within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2025 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. This Registration Statement is being filed to register 3,000,000 ADSs under the 2025 Inducement Plan.

The 2018 Plan provides for an annual automatic increase in the number of ordinary shares represented by ADSs reserved for issuance under the 2018 Plan. This Registration Statement is being filed to register 10,645,656 ADSs under the 2018 Plan. Such ADSs represent the increase that occurred on October 1, 2025 and are being registered in addition to the ADSs for which registration statements on Form S-8 (File No. 333-226457), Form S-8 (File No. 333-273776), Form S-8 (File No. 333-275301) and Form S-8 (File No. 333-283229) were filed with the Commission on July 31, 2018, August 7, 2023, November 3, 2023 and November 14, 2024, respectively (the "Prior Registration Statements"). Accordingly, the contents of the Prior Registration Statements are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

**PART I** 

**INFORMATION REQUIRED TO BE IN THE SECTION 10(A) PROSPECTUS** 

In accordance with the instructional note to Part I of Form S-8, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II** 

**Item 3. Incorporation of Documents By Reference.** 

The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on Form 10-K for the fiscal year
ended December 31, 2024, filed with the Commission on [March 20, 2025.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000019/autl-20241231.htm)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registrant's Quarterly Reports on Form 10-Q for the
quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the Commission on [May 8, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000039/autl-20250331.htm) , [August 12, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000067/autl-20250630.htm) and [November 12, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000088/autl-20250930.htm) , respectively.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Registrant's Reports on Form 8-K furnished to the SEC on [January 13, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000004/autl-20250113.htm) (except for the information furnished under Item 7.01 and exhibit 99.1 thereto), [March 20, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autl-20250320.htm) (except for the
information furnished under Items 2.02 and 7.01 and exhibits 99.1 and 99.2 thereto), [April 3, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000119312525072356/d945856d8k.htm) , [April 23, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000022/autl-20250423.htm) (except for the information furnished under Item 7.01 thereto), [May 8, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000032/autl-20250508.htm) (except for the information furnished under Items
2.02 and 7.01 and exhibits 99.1 and 99.2 thereto), [May 30, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000119312525132111/d908343d8k.htm) (except for the information furnished under exhibits 99.1, 99.2 and 99.3
thereto), [June 2, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000043/autl-20250602.htm) (except for the information furnished under exhibits 99.1, 99.2 and 99.3 thereto), [June 27, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000046/autl-20250626.htm) , [August 12, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/autl-20250812.htm) (except for the information furnished under Items 2.02 and 7.01 and exhibits 99.1 and 99.2 thereto) and [November 12, 2025](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000081/autl-20251112.htm) (except for the information furnished under Items 2.02 and 7.01 and exhibits 99.1 and 99.2 thereto); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the descriptions of the Registrant's ADSs and ordinary shares contained in the Registrant's
Registration Statement on [<u>Form 8-A</u>](http://www.sec.gov/Archives/edgar/data/1730463/000119312518196920/d531832d8a12b.htm) filed on June 19, 2018 (File No. 001-38547) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as updated by the description of the Registrant's securities registered pursuant to
Section 12 of the Exchange Act contained in the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, including any amendment or report filed for the purpose of
updating such description.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such
securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific section of such statements as set forth therein.

------

**Item 8. Exhibits.** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | <br>**Description** | **Schedule<br>Form** | **File<br>Number** | **Exhibit** | **Filing<br>Date** |
| 4.1 | [Articles of Association of Autolus Therapeutics plc.](http://www.sec.gov/Archives/edgar/data/1730463/000119312518196344/d531832dex31.htm) | Form F-1/A | 333-224720 | 3.1 | 6/19/18 |
| 4.2 | [Deposit Agreement by and among the registrant, Citibank, N.A., as the Depositary bank and the holders and beneficial owners of American Depositary Shares issued thereunder.](http://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autolusexhibit211q19.htm) | Form 20-F | 001-38547 | 2.1 | 2/25/19 |
| 4.3 | [Form of American Depositary Receipt (included in Exhibit 4.2).](http://www.sec.gov/Archives/edgar/data/1730463/000173046319000004/autolusexhibit211q19.htm) | Form 20-F | 001-38547 | 2.1 | 2/25/19 |
| 5.1\* | [Opinion of Cooley (UK) LLP.](d813559dex51.htm) |  |  |  |  |
| 10.1+ | [Autolus Therapeutics plc - 2025 Employee Share Purchase Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000067/ex-101xautolustherapeuti.htm) | Form 10-Q | 001-38547 | 10.1 | 8/12/25 |
| 10.2+ | [Autolus Therapeutics plc - 2025 UK Sharesave Sub-plan.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000067/ex-102xautolustherapeuti.htm) | Form 10-Q | 001-38547 | 10.1 | 8/12/25 |
| 10.3 | [Autolus Therapeutics plc - 2025 Inducement Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000039/ex-101xautolustherapeutics.htm) | Form 10-Q | 001-38547 | 10.1 | 5/8/25 |
| 10.4 | [Form of Stock Option Grant Notice and Stock Option Agreement for the Autolus Therapeutics plc - 2025 Inducement Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000039/ex-102xautolustherapeutics.htm) | Form 10-Q | 001-38547 | 10.2 | 5/8/25 |
| 10.5 | [Form of Restricted Stock Unit Grant Notice and Award. Agreement for the Autolus Therapeutics plc - 2025 Inducement Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000173046325000039/ex-103xautolustherapeutics.htm) | Form 10-Q | 001-38547 | 10.3 | 5/8/25 |
| 10.6 | [Autolus Therapeutics plc 2018 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000119312518196344/d531832dex103.htm) | Form F-1/A | 333-224720 | 10.3 | 6/19/18 |
| 10.7 | [Non-Employee Sub-Plan to the Autolus Therapeutics plc 2018 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1730463/000119312518196344/d531832dex104.htm) | Form F-1/A | 333-224720 | 10.4 | 6/19/18 |
| 23.1\* | [Consent of Ernst & Young LLP.](d813559dex231.htm) |  |  |  |  |
| 23.2\* | [Consent of Cooley (UK) LLP (included in Exhibit 5.1).](d813559dex51.htm) |  |  |  |  |
| 24.1\* | [Power of Attorney (included on the signature page of this Registration Statement).](#sig) |  |  |  |  |
| 107\* | [Filing Fee Table.](d813559dexfilingfees.htm) |  |  |  |  |

---

+ Indicates management contract or compensatory plan.

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, the City of London, United Kingdom, on November 18, 2025.

---

| | |
|:---|:---|
|  | **AUTOLUS THERAPEUTICS PLC** |
| By: | /s/ Christian Itin, Ph.D. |
|  | Name: Christian Itin, Ph.D. |
|  | Title: Chief Executive Officer |

---

**POWER OF ATTORNEY** 

We, the undersigned officers and directors of Autolus Therapeutics plc, hereby severally constitute and appoint Christian Itin and Alex Driggs our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 filed herewith and any and all amendments (including post-effective amendments) to said Registration Statement, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all such things in our name and on our behalf in our capacities as officers and directors to enable Autolus Therapeutics plc to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming all that said attorneys, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Christian Itin, Ph.D.<br> Christian Itin, Ph.D. | Chief Executive Officer and Director<br>(*Principal Executive Officer*) | November 18, 2025 |
| /s/ Robert Dolski<br> Robert Dolski | Chief Financial Officer<br>(*Principal Financial Officer*) | November 18, 2025 |
| /s/ Patrick McIIvenny<br> Patrick McIIvenny | Senior Vice President, Finance<br>*(Principal Accounting Officer)* | November 18, 2025 |
| /s/ Michael Bonney<br> Michael Bonney | Chairman of the Board of Directors | November 18, 2025 |
| /s/ Robert Azelby<br> Robert Azelby | Director | November 18, 2025 |
| /s/ Linda Bain<br> Linda Bain | Director | November 18, 2025 |
| /s/ John Berriman<br> John Berriman | Director | November 18, 2025 |
| /s/ Cynthia Butitta<br> Cynthia Butitta | Director | November 18, 2025 |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Robert Iannone, M.D., M.S.C.E.<br> Robert Iannone, M.D., M.S.C.E. | Director | November 18, 2025 |
| /s/ Elisabeth Leiderman, M.D<br> Elisabeth Leiderman, M.D | Director | November 18, 2025 |
| /s/ Ravi Rao, M.D.<br> Ravi Rao, M.D. | Director | November 18, 2025 |
| /s/ William Young, Ph.D.<br> William Young, Ph.D. | Director | November 18, 2025 |

---

**SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE** 

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Autolus Therapeutics plc has signed this registration statement or amendment thereto on November 18, 2025.

---

| | |
|:---|:---|
|  | **AUTOLUS INC.** |
| By: | /s/ Christian Itin, Ph.D. |
| Name: | Christian Itin, Ph.D. |
| Title: | Chief Executive Officer |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g813559g1118074610361.jpg)

Claire Keast-Butler

+44 (0) 20 7556 4211

ckeastbutler@cooley.com

Autolus Therapeutics plc

The Mediaworks

191 Wood Lane

London W12 7FP

United Kingdom

18 November 2025

Ladies and Gentlemen:

---

| | |
|:---|:---|
| **Re:** | **Autolus Therapeutics plc – Registration Statement on Form S-8 – Exhibit 5.1**  |

---

**1.** **INTRODUCTION** 

1.1 We have acted as English legal advisers to Autolus Therapeutics plc, a public limited company incorporated in
England and Wales (the "**Company** "), in relation to the preparation and filing of the registration statement on Form S-8 to which this opinion letter is attached as an exhibit (such
registration statement, as amended, including the documents incorporated by reference therein, the "**Registration Statement**") filed with the United States Securities and Exchange Commission (the "**SEC**") pursuant
to the United States Securities Act of 1933, as amended (the "**Securities Act**") and the rules and regulations promulgated thereunder.

1.2 As set out in the Registration Statement, it is proposed that up to 16,645,656 ordinary shares of the Company
having a nominal value of $0.000042 each (each an "**Ordinary Share**" and such Ordinary Shares being the "**Shares**") will be allotted and issued upon the exercise or settlement of equity awards to be granted under:
(i) the Autolus Therapeutics plc 2018 Equity Incentive Plan adopted by the board of directors (the "**Board**" or the "**Directors**") on 15 June 2018 and approved by the Company's shareholders on
15 June 2018 (the "**2018 Incentive Plan**") which includes Ordinary Shares reserved for issuance under the Non-Employee Sub Plan to the 2018 Incentive Plan (the "**Sub-Plan**" and, collectively with the 2018 Incentive Plan, the "**2018 Plan** "); (ii) the Autolus Therapeutics plc 2025 Employee Share Purchase Plan adopted by the Board on 20 May 2025
and approved by the Company's shareholders on 26 June 2025 (the "**2025 ESPP** "); and (iii) the Autolus Therapeutics plc 2025 Inducement Plan adopted by the Board on 23 March 2025 (the "**2025 Inducement Plan** ", and, together with the 2018 Plan and the 2025 ESPP, the "**Plans** ").

1.3 We are rendering this letter at the request of the Company in connection with the Registration Statement. We
have taken instructions solely from the Company.

1.4 Except as otherwise defined in this letter, capitalised terms used have the respective meanings given to them
in the Registration Statement and headings are for ease of reference only and shall not affect interpretation.

1.5 All references to legislation in this letter are to the legislation of England unless the contrary is
indicated, and any reference to any provision of any legislation shall include any amendment, modification, re-enactment or extension thereof, as in force on the date of this letter.

Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ, UK

t: +44 (0) 20 7583 4055 f: +44 (0) 20 7785 9355 cooley.com

Cooley (UK) LLP is a limited liability partnership and is registered in England and Wales with registered number OC395270. Our registered office is at the address above.

Cooley (UK) LLP is authorised and regulated by the Solicitors Regulation Authority (SRA number 617791). A list of the members of Cooley (UK) LLP and their professional qualifications is open to inspection at its registered office. The word 'partner,' used in relation to Cooley (UK) LLP, refers to a member of Cooley (UK) LLP or an employee or consultant of Cooley (UK) LLP (or any affiliated firm) of equivalent standing.

------

Page Two

**2.** **DOCUMENTS** 

For the purpose of issuing this letter, we have reviewed the following documents only:

2.1 a draft PDF copy of the Registration Statement to be filed with the SEC on 18 November 2025;

2.2 a PDF copy of the 2018 Plan;

2.3 a PDF copy of the executed written resolutions of the Board passed on 15 June 2018 approving, *inter alia*, the 2018 Plan (the "**2018 Board Written Resolutions** ");

2.4 a PDF copy of the executed written resolutions passed by the shareholders of the Company on 15 June 2018
approving, *inter alia*, the 2018 Plan (the "**2018 Shareholder Resolutions** ");

2.5 a PDF copy of the 2025 ESPP;

2.6 a PDF copy of the 2025 Inducement Plan;

2.7 a PDF copy of the written resolutions of the Board passed on 27 March 2025 approving, *inter alia*,
the 2025 Inducement Plan (the "**March 2025 Board Written Resolutions** ");

2.8 a PDF copy of the written resolutions of the compensation committee of the Board (the "**Compensation Committee**") passed on 18 May 2025, in which it was resolved, *inter alia*, to approve the 2025 ESPP and recommend the same to the Board for approval (the "**Committee Written Resolutions** ");

2.9 a PDF copy of the written resolutions of the Board passed on 20 May 2025 approving, *inter alia*, the
2025 ESPP (the "**May 2025 Board Written Resolutions** ", and, together with the 2018 Board Written Resolutions and the March 2025 Board Written Resolutions, the "**Board Written Resolutions** ");

2.10 a PDF copy of the resolutions passed at the annual general meeting of the Company held on 28 June 2024
(the "**2024 Annual General Meeting**") signed by a director of the Company at which meeting it was resolved, *inter alia*, to (i) authorise the Directors for the purposes of section 551 of the Companies Act 2006, as
amended (the "**Companies Act**") to allot shares in the Company or grant rights to subscribe for, or convert any security into, shares in the Company up to a maximum aggregate nominal amount of $8,400 and (ii) empower the
Directors to allot equity securities (as defined in the Companies Act) for cash pursuant to the authority referred to in (i) as if section 561(1) of the Companies Act did not apply to the allotment (the "**2024 Shareholder Resolutions** ");

2.11 a PDF copy of the resolutions passed at the annual general meeting of the Company held on 26 June 2025
(the "**2025 Annual General Meeting**") signed by a director of the Company at which meeting it was resolved, *inter alia*, to approve the 2025 ESPP (the "**2025 Shareholder Resolutions** ");

2.12 PDF copies of the certificate of incorporation of the Company dated 2 February 2018 and the certificate of
incorporation on re-registration of the Company as a public company dated 18 June 2018; and

2.13 a PDF copy of the current articles of association of the Company adopted on 26 June 2018 (the
" **Articles** ").

**3.** **SEARCHES** 

In addition to examining the documents referred to in paragraph 2 (*Documents*), we have carried out the following searches only:

3.1 an online search at Companies House in England and Wales ()"**Companies House**") with respect to
the Company, carried out at 09:48 a.m. (London time) on 18 November 2025 (the "**Companies House Search** "); and

3.2 an online enquiry of the Central Registry of Winding-up Petitions at
the Insolvency and Companies List in England and Wales (the "**Central Registry**") with respect to the Company, carried out at 10:05 a.m. (London time) on 18 November 2025 (the "**Central Registry Enquiry**" and,
together with the Companies House Search, the "**Searches** ").

------

Page Three

**4.** **OPINION** 

Subject to the assumptions set out in paragraph 5 (*Assumptions*), the scope of the opinion set out in paragraph 6 (*Scope of Opinion*) and the reservations set out in paragraph 7 (*Reservations*), and subject further to the following:

4.1 the Registration Statement, as finally amended, having become effective under the Securities Act;

4.2 the delegation of authority to the Compensation Committee in respect of each Plan having been validly effected;

4.3 the Directors or the Compensation Committee having validly granted the awards in respect of the Shares under
each Plan;

4.4 the Directors or the Compensation Committee, as applicable, having validly resolved to allot and issue the
Shares, or grant rights to subscribe for the Shares, at duly convened and quorate meetings of the Board or the Compensation Committee or by way of duly passed written resolutions of the Board or the Compensation Committee in compliance with all
applicable laws and regulations and with such resolutions being in full force and effect and not having been rescinded or amended;

4.5 the receipt in full of payment for the Shares in an amount of "cash consideration" (as defined in
section 583(3) of the Companies Act) of not less than the aggregate nominal value for such Shares, assuming in each case that the individual grants or awards under each Plan are duly authorised by all necessary corporate action and duly granted or
awarded and exercised in accordance with the requirements of applicable law, the Articles and the relevant Plan (and the agreements and awards duly adopted thereunder and in accordance therewith); and

4.6 valid entries having been made in relation to the allotment and issue of the Shares in the books and registers
of the Company,

it is our opinion that, as at today's date, the Shares, if and when allotted and issued, registered in the name of the recipient in the register of members of the Company and delivered in accordance with the terms and conditions referred to in the relevant Plan, as described in the Registration Statement, will be duly and validly authorised and issued, fully paid or credited as fully paid (subject to the receipt of valid consideration by the Company for the issue thereof) and will not be subject to any call for payment of further capital.

**5.** **ASSUMPTIONS** 

In giving the opinion in this letter, we have assumed (without making enquiry or investigation) that:

5.1 all signatures, stamps and seals on all documents are genuine. All original documents are complete, authentic
and up-to-date, and all documents submitted to us as a copy (whether by email or otherwise) are complete and accurate and conform to the original documents of which they
are copies and that no amendments (whether oral, in writing or by conduct of the parties) have been made to any of the documents since they were examined by us;

5.2 where a document has been examined by us in draft or specimen form, it will be or has been duly executed in the
form of that draft or specimen;

5.3 the Articles referred to in paragraph 2.13 (*Documents*) of this letter remain in full force and effect,
and no alteration has been made or will be made to the Articles, in each case prior to the relevant date of the granting of rights to subscribe for the Shares and/or the allotment and issue of the Shares (each such date, an "**Allotment Date** ");

------

Page Four

5.4 at the time of each allotment and issue of any Shares the Company shall have received in full "cash
consideration" (as such term is defined in section 583(3) of the Companies Act) equal to the subscription price payable for such Shares and shall have entered the holder or holders thereof in the register of members of the Company showing that
all such Shares shall have been fully paid up as to their nominal value and any premium thereon as at each Allotment Date;

5.5 each Plan has been validly adopted and remains in full force and effect, and no alteration has been made or
will be made to any Plan prior to any Allotment Date;

5.6 in relation to any allotment and issue of any Shares by the Company pursuant to a Plan, the recipient shall
have become entitled to such Shares under the terms of the relevant Plan and such Shares, or rights over Shares, where applicable, will be fully vested each in accordance with the terms of the relevant Plan and such recipient has or will have
complied with all other requirements of the relevant Plan in connection with the allotment and issue of such Shares;

5.7 all awards will be made under the terms of the relevant Plan, that the terms of all awards will not materially
deviate from the terms set out in the relevant Plan, and that any Shares will be allotted and issued in accordance with the terms set out in the relevant Plan and in accordance with the Articles and applicable laws;

5.8 each Plan (other than the Sub-Plan) qualifies as an
"employees' share scheme" as defined in section 1166 of the Companies Act;

5.9 immediately prior to each Allotment Date, the Directors shall have sufficient authority and powers conferred
upon them to allot and issue such Shares and grant such rights to acquire the Shares (as applicable) under section 551 of the Companies Act (unless such allotment and issue or grant is exempt under section 549(2) of the Companies Act) and under
section 570 of the Companies Act as if section 561 of the Companies Act did not apply to such allotment and issue or grant (unless such allotment and issue or grant is exempt from section 561 of the Companies Act pursuant to section 566 of the
Companies Act) pursuant to the 2024 Shareholder Resolutions, or if the relevant authorities and powers under the 2024 Shareholder Resolutions have expired or been fully utilised or renewed or revoked the Company in general meeting having duly and
validly resolved to grant such authorities and powers to the Directors in an amount sufficient to allot and issue the Shares, and the Directors shall not allot or issue (or purport to allot or issue) Shares and shall not grant rights (or purport to
grant rights) to acquire Shares in excess of such powers or in breach of any other limitation on their power to allot and issue Shares or grant rights to acquire Shares;

5.10 no Shares shall be allotted or issued, or are or shall be committed to be allotted or issued, at a discount to
their nominal value (whether in dollars or equivalent in any other currency);

5.11 all documents, forms and notices which should have been delivered to Companies House in respect of the Company
have been so delivered;

5.12 the information revealed by the Searches is true, accurate, complete and up-to-date in all respects, and there is no information which should have been disclosed by the Searches that has not been disclosed for any reason and there has been no alteration in the status or condition
of the Company since the date and time that the Searches were made and that the results of the Searches will remain complete and accurate as at each Allotment Date;

5.13 in relation to the allotment and issue of the Shares, the Directors have acted and will act in the manner
required by section 172 of the Companies Act and the Shares will be allotted and issued in good faith and on bona fide commercial terms and on arms' length terms and for the purpose of carrying on the business of the Company and that there are
reasonable grounds for believing that the allotment and issue of the Shares will promote the success of the Company for the benefit of its members as a whole;

5.14 there has not been and will not be any bad faith, breach of trust, fraud, coercion, duress or undue influence
on the part of any of the Directors in relation to any allotment and issue of Shares;

------

Page Five

5.15 the resolutions set out in the Board Written Resolutions and the Committee Written Resolutions referred to in
paragraphs 2.3, 2.7, 2.8 and 2.9 (*Documents*) were validly passed as written resolutions in accordance with the articles of association of the Company then in force, that all eligible Directors (being all the Directors who would have been
entitled to vote on the matter had it been proposed as a resolution at a Directors' meeting or meeting of the Compensation Committee, as applicable, but excluding any Director whose vote is not to be counted in respect of a particular matter)
signed one or more copies of the Board Written Resolutions and the Committee Written Resolutions, that all relevant provisions of the Companies Act and the articles of association then in force were complied with and were duly observed (including,
if applicable, those relating to the declaration of each Director's interests or their power to vote) and such resolutions were duly adopted, and have not been revoked or varied and remain in full force and effect and will remain so as at each
Allotment Date;

5.16 each meeting of the Directors or the Compensation Committee referred to in paragraphs 4.3 and 4.4 of this
letter will be duly conducted as described therein, duly constituted and convened and all constitutional, statutory and other formalities will be duly observed (including, if applicable, those relating to the declaration of Directors'
interests or the power of interested Directors to vote), a quorum will be present throughout, the requisite majority of Directors will vote in favour of approving the resolutions and the resolutions passed at that meeting of the Board or
Compensation Committee, as applicable, will be duly adopted, and will not be revoked or varied and will remain in full force and effect and will remain so as at each Allotment Date;

5.17 any written resolutions of the Directors or the Compensation Committee referred to in paragraphs 4.3 and 4.4 of
this letter will be validly passed as written resolutions in accordance with the articles of association of the Company in effect as at such time, that all eligible Directors (being all the Directors who would have been entitled to vote on the
matter had it been proposed as a resolution at a Directors' meeting, or a meeting of the Compensation Committee, as applicable, but excluding any Director whose vote is not to be counted in respect of a particular matter) will sign one or more
copies of the resolutions, that all relevant provisions of the Companies Act and the Articles will be complied with and duly observed (including, if applicable, those relating to the declaration of Directors' interests or the power of
interested Directors to vote) and such resolutions will be duly adopted, and will not be revoked or varied and will remain in full force and effect once passed and will remain so as at each Allotment Date;

5.18 the 2018 Shareholder Resolutions referred to in paragraph 2.4 (*Documents*) were duly passed as written
resolutions on 15 June 2018, that the requisite majority of eligible shareholders signed one or more copies of the written resolutions, that all provisions of the Companies Act and the articles of association of the Company in effect at the
relevant time were duly observed and that such resolutions were duly passed and have not been revoked or varied and remain in full force and effect and will remain so as at each Allotment Date, and that all filings required to be made with Companies
House in connection therewith have been made within the relevant time limits;

5.19 the 2024 Annual General Meeting and 2025 Annual General Meeting were duly convened and held on 28 June
2024 and 26 June 2025 respectively, at which all constitutional, statutory and other formalities were duly observed, a quorum of shareholders was present throughout and the 2024 Shareholder Resolutions and 2025 Shareholder Resolutions referred
to in paragraphs 2.10 and 2.11 respectively (*Documents*) were duly passed and have not been revoked or varied and remain in full force and effect and will remain in full force and effect as at each Allotment Date, and that all filings required
to be made with Companies House in connection therewith were made within the relevant time limits;

5.20 the resolutions of the shareholders of the Company referred to in paragraph 5.9 will be duly passed as
resolutions of the Company at a duly convened and held general meeting of the Company, all constitutional, statutory and other formalities will be observed in respect of such meeting and such resolutions will not have expired and will not be revoked
or varied prior to each Allotment Date and will remain in full force and effect as at each Allotment Date;

------

Page Six

5.21 the Company has complied and will comply with all applicable anti-terrorism, anti-money laundering, sanctions
and human rights laws and regulations and that each grant of rights to acquire Shares under each Plan and that each allotment and issue of Shares pursuant to each Plan will be consistent with all such laws and regulations;

5.22 no Shares or rights to subscribe for Shares have been or shall be offered to the public in the United Kingdom
in breach of the Financial Services and Markets Act 2000 ()"**FSMA** "), EU Regulation (EU) 2017/1129 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 or, as applicable, the
Public Offers and Admissions to Trading Regulations 2024 and the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market sourcebook or of any other United Kingdom laws or regulations concerning offers of
securities to the public, and no communication has been or shall be made in relation to the Shares in breach of section 21 (*Restrictions on financial promotion*) of FSMA or any other United Kingdom laws or regulations relating to offers or
invitations to subscribe for, or to acquire rights to subscribe for or otherwise acquire, shares or other securities.

5.23 in issuing and allotting and granting rights to acquire Shares and administering each Plan, the Company is not
carrying on a regulated activity (within the meaning of section 19 (*The general prohibition*) of FSMA); and

5.24 the Company has not taken any corporate or other action nor have any steps been taken or legal proceedings been
started against the Company for the liquidation, winding-up, dissolution or reorganisation of, or for the appointment of a liquidator, receiver, trustee, administrator, administrative receiver or similar
officer of, any such party (including the Company) or all or any of its or their assets (or any analogous proceedings in any jurisdiction) and no such steps or proceedings will have been taken as at each Allotment Date, and the Company is not unable
to pay its debts as they fall due within the meaning of section 123 of the Insolvency Act 1986, as amended (the "**Insolvency Act**") and will not become unable to pay its debts within the meaning of that section as a result of any of
the transactions contemplated herein, is not insolvent and has not been dissolved (although the Searches gave no indication that any winding-up, dissolution or administration order or appointment of a
receiver, administrator, administrative receiver or similar officer has been made with respect to the Company) and such actions and steps will not have been taken as at any Allotment Date.

**6.** **SCOPE OF OPINION** 

6.1 The opinion given in this letter is limited to English law as it would be applied by English courts on the date
of this letter.

6.2 We express no opinion in this letter on the laws of any other jurisdiction. We have not investigated the laws
of any country other than England and we assume that no foreign law affects the opinion stated in paragraph 4 (*Opinion*).

6.3 We express no opinion as to any agreement, instrument or other document other than as specified in this letter.
For the purposes of giving the opinion in paragraph 4 (*Opinion*), we have only examined and relied on those documents set out in paragraph 2 (*Documents*) and made those searches and enquiries set out in paragraph 3 (*Searches*),
respectively. We have made no further enquiries concerning the Company or any other matter in connection with the giving of the opinion in paragraph 4 (*Opinion*).

6.4 No opinion is expressed with respect to taxation in the United Kingdom or otherwise in this letter.

6.5 We have not been responsible for investigating or verifying the accuracy of the facts or the reasonableness of
any statement of opinion or intention, contained in or relevant to any document referred to in this letter, or that no material facts have been omitted therefrom.

------

Page Seven

6.6 The opinion given in this letter is given on the basis of each of the assumptions set out in paragraph 5
(*Assumptions*) and is subject to each of the reservations set out in paragraph 7 (*Reservations*) to this letter. The opinion given in this letter is strictly limited to the matters stated in paragraph 4 (*Opinion*) and does not
extend, and should not be read as extending, by implication or otherwise, to any other matters.

6.7 This letter only applies to those facts and circumstances which exist as at today's date and we assume no
obligation or responsibility to update or supplement this letter to reflect any facts or circumstances which may subsequently come to our attention, any changes in laws which may occur after today, or to inform the addressee of any change in
circumstances happening after the date of this letter which would alter the opinion given in this letter.

6.8 We have not been responsible for investigation or verification of statements of fact (including statements as
to foreign law) or to the reasonableness of any statements of opinion in the Registration Statement, or that no material facts have been omitted therefrom.

6.9 This letter is given by Cooley (UK) LLP and no partner or employee assumes any personal responsibility for it
nor shall owe any duty of care in respect of it.

6.10 This letter, the opinion given in it, and any non-contractual obligations arising out of or in connection with this letter and/or the opinion given in it, are governed by and shall be construed in accordance with English law as at the date of this letter.

**7.** **RESERVATIONS** 

7.1 The Companies House Search described at paragraph 3.1 (*Searches*) is not capable of revealing
conclusively whether or not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a winding-up order has been made or a resolution passed for the winding-up of a company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) an administration order has been made; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a receiver, administrative receiver, administrator or liquidator has been appointed,

since notice of these matters may not be filed with the Registrar of Companies in England and Wales immediately and, when filed, may not be entered on the public database or recorded on the public microfiches of the relevant company immediately.

In addition, such a company search is not capable of revealing, prior to the making of the relevant order, whether or not a winding-up petition or a petition for an administration order has been presented.

7.2 The Central Registry Enquiry described at paragraph 3.2 (*Searches*) relates only to a compulsory winding-up and is not capable of revealing conclusively whether or not a winding-up petition in respect of a compulsory winding-up has
been presented, since details of the petition may not have been entered on the records of the Central Registry immediately or, in the case of a petition presented to a District Registry and/or County Court in England and Wales, may not have been
notified to the Central Registry and entered on such records at all, and the response to an enquiry only relates to the period since approximately 2016 for petitions presented in London and since approximately 2019 for petitions presented to a
District Registry and/or County Court in England and Wales. We have not made enquiries of any District Registry or County Court in England and Wales.

7.3 The opinion set out in this letter is subject to: (i) any limitations arising from applicable laws
relating to insolvency, bankruptcy, administration, reorganisation, liquidation, moratoria, schemes or analogous circumstances; and (ii) an English court exercising its discretion under section 426 of the Insolvency Act (co-operation between courts exercising jurisdiction in relation to insolvency) to assist the courts having the corresponding jurisdiction in any part of the United Kingdom or any relevant country or territory.

7.4 We express no opinion as to matters of fact.

------

Page Eight

7.5 We have made no enquiries of any individual connected with the Company.

7.6 We express no opinion on the compliance of the Plans, or the compliance of any award to be made under the
Plans, with the rules or regulations of the Nasdaq Global Select Market or the rules or regulations of any other securities exchange that are applicable to the Company.

7.7 A certificate, documentation, notification, opinion or the like might be held by the English courts not to be
conclusive if it can be shown to have an unreasonable or arbitrary basis or in the event of a manifest error.

7.8 We express no opinion in relation to the legality, enforceability or validity of the Plans or any award
agreement to be entered into pursuant to the Plans. In particular, but without prejudice to the generality of the foregoing, we have assumed that the Shares to be allotted under the Plans or any such award agreement will be paid up in full (as to
their nominal value and any premium) in cash (within the meaning of section 583(1) of the Companies Act) and we express no opinion as to whether any consideration other than "cash consideration" (as such term is defined in section 583(3)
of the Companies Act) which might be paid, or purport to be paid, for the Shares would result in such Shares being validly issued, fully paid and not subject to any call for payment of further capital.

7.9 If (a) the Company or any person to whom the Shares are to be allotted and issued (a "**Relevant Person**") is the target of economic or financial sanctions or other restrictive measures imposed in any jurisdiction ()"**Sanctions**") or is owned or controlled (directly or indirectly) by or is acting on behalf of or at the
direction of or is otherwise connected with a person who is a target of Sanctions or (b) a Relevant Person is incorporated or resident in or operating from a country or territory that is a target of Sanctions or (c) the rights or
obligations of a Relevant Person is otherwise affected by Sanctions, then the rights and obligations of such Relevant Person under the Plans may be void and/or unenforceable.

7.10 We express no opinion in this letter on the application or potential application of the National Security and
Investment Act 2021 in relation to the Plans or any transaction contemplated thereby.

**8.** **DISCLOSURE AND RELIANCE** 

8.1 This letter is addressed to you solely for your benefit in connection with the Registration Statement. We
consent to the filing of this letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under section 7 of the Securities Act or the rules and
regulations promulgated thereunder.

8.2 This letter may not be relied upon by you for any other purpose, or furnished to, assigned to, quoted to, or
relied upon by any other person, firm or other entity for any purpose, other than for the purpose set out in above in paragraph 8.1, without our prior written consent, which may be granted or withheld at our sole discretion.

Yours faithfully

/s/ Cooley (UK) LLP

**Cooley (UK) LLP**

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Autolus Therapeutics plc of the following plans:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2025 Employee Share Purchase Plan

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2025 Inducement Plan

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2018 Equity Incentive Plan

of our report dated March 20, 2025, with respect to the consolidated financial statements of Autolus Therapeutics plc included in its Annual Report (Form 10-K) for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Reading, United Kingdom

November 18, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Autolus Therapeutics plc**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | 2025 Employee Share Purchase Plan, ordinary shares | Other | 3000000 | $1.30 | $3900000.00 | 0.0001381 | $538.59 |
| 2 | Equity | 2025 Inducement Plan, Ordinary shares, ordinary shares | Other | 3000000 | $1.30 | $3900000.00 | 0.0001381 | $538.59 |
| 3 | Equity | 2018 Equity Incentive Plan, ordinary shares | Other | 10645656 | $1.30 | $13839353.00 | 0.0001381 | $1911.22 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $21639353.00  |  | $2988.40  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $2988.40  |

---

 **Offering Note** <br>

<sup>1</sup> (1) These ordinary shares of Autolus Therapeutics plc (the "Registrant"), $0.000042 par value per share (the "Ordinary Shares"), may be represented by the Registrant's American Depositary Shares ("ADSs"), each of which represents one Ordinary Share. The Registrant's ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate registration statement on Form F-6 (File No. 333-224837), as amended. (2) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional Ordinary Shares that become issuable under he plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding Ordinary Shares. (3) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act. The proposed maximum aggregate offering price per share is based on the average of the high and low prices of the ADSs on November 13, 2025, as reported on the Nasdaq Global Select Market. (4) Represents Ordinary Shares that are authorized for issuance pursuant to the Registrant's 2025 Employee Share Purchase Plan.

<sup>2</sup> (1) These ordinary shares of Autolus Therapeutics plc (the "Registrant"), $0.000042 par value per share (the "Ordinary Shares"), may be represented by the Registrant's American Depositary Shares ("ADSs"), each of which represents one Ordinary Share. The Registrant's ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate registration statement on Form F-6 (File No. 333-224837), as amended. (2) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional Ordinary Shares that become issuable under he plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding Ordinary Shares. (3) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act. The proposed maximum aggregate offering price per share is based on the average of the high and low prices of the ADSs on November 13, 2025, as reported on the Nasdaq Global Select Market. (5) Represents Ordinary Shares that that are authorized for issuance pursuant to the Registrant's 2025 Inducement Plan.

<sup>3</sup> (1) These ordinary shares of Autolus Therapeutics plc (the "Registrant"), $0.000042 par value per share (the "Ordinary Shares"), may be represented by the Registrant's American Depositary Shares ("ADSs"), each of which represents one Ordinary Share. The Registrant's ADSs issuable upon deposit of the Ordinary Shares registered hereby were registered pursuant to a separate registration statement on Form F-6 (File No. 333-224837), as amended. (2) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional Ordinary Shares that become issuable under he plans set forth herein by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of the Registrant's outstanding Ordinary Shares. (3) Estimated solely for the purpose of computing the amount of the registration fee pursuant to Rules 457(c) and 457(h) under the Securities Act. The proposed maximum aggregate offering price per share is based on the average of the high and low prices of the ADSs on November 13, 2025, as reported on the Nasdaq Global Select Market. (6) Represents Ordinary Shares that were added to the shares authorized for issuance under the Registrant's 2018 Equity Incentive Plan (the "2018 EIP") on October 1, 2025, pursuant to an automatic increase provision contained in the 2018 EIP.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---